Pharma Deko Plc engages in manufacturing, packaging, and marketing pharmaceutical and consumer products in Nigeria.
Price History & Performance
|Historical stock prices|
|Current Share Price||₦2.60|
|52 Week High||₦1.09|
|52 Week Low||₦2.85|
|1 Month Change||60.49%|
|3 Month Change||114.88%|
|1 Year Change||73.33%|
|3 Year Change||54.76%|
|5 Year Change||60.49%|
|Change since IPO||-10.65%|
Recent News & Updates
|PHARMDEKO||NG Beverage||NG Market|
Return vs Industry: PHARMDEKO exceeded the NG Beverage industry which returned -4.9% over the past year.
Return vs Market: PHARMDEKO exceeded the NG Market which returned 40.4% over the past year.
Stable Share Price: PHARMDEKO is more volatile than 90% of NG stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PHARMDEKO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of NG stocks.
About the Company
Pharma Deko Plc engages in manufacturing, packaging, and marketing pharmaceutical and consumer products in Nigeria. It operates through three segments: Pharma, Consumer, and Contract. The company offers pharmaceutical products, such as Vitacee syrups and drops, Pharmadec syrups and drops, Brett mouthwash, Hexedene oral care medication, Parkalin range of cough syrup, Parkaling Pediatrics, Revitone Blood Tonic, Salins Liniment, Antasil tablets, Omepraz capsules, Sparxin, Amoquin and Garlic tablets, Pidiclox dry powder and capsules, Anuproct suppository, and Parkaprim tablets and suspension, as well as paracetamol under the Phardol Drops brand.
Pharma Deko Fundamentals Summary
|PHARMDEKO fundamental statistics|
Is PHARMDEKO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHARMDEKO income statement (TTM)|
|Cost of Revenue||₦405.33m|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||-1.50|
|Net Profit Margin||-70.57%|
How did PHARMDEKO perform over the long term?See historical performance and comparison
Is Pharma Deko undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHARMDEKO (NGN2.6) is trading below our estimate of fair value (NGN55.85)
Significantly Below Fair Value: PHARMDEKO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHARMDEKO is unprofitable, so we can't compare its PE Ratio to the African Beverage industry average.
PE vs Market: PHARMDEKO is unprofitable, so we can't compare its PE Ratio to the NG market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHARMDEKO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PHARMDEKO is good value based on its PB Ratio (0.6x) compared to the NG Beverage industry average (0.9x).
How is Pharma Deko forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Food, Beverage & Tobacco industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharma Deko has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Pharma Deko performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHARMDEKO is currently unprofitable.
Growing Profit Margin: PHARMDEKO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PHARMDEKO is unprofitable, and losses have increased over the past 5 years at a rate of 56.9% per year.
Accelerating Growth: Unable to compare PHARMDEKO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHARMDEKO is unprofitable, making it difficult to compare its past year earnings growth to the Beverage industry (19.7%).
Return on Equity
High ROE: PHARMDEKO has a negative Return on Equity (-32.97%), as it is currently unprofitable.
How is Pharma Deko's financial position?
Financial Position Analysis
Short Term Liabilities: PHARMDEKO's short term assets (NGN353.3M) do not cover its short term liabilities (NGN1.0B).
Long Term Liabilities: PHARMDEKO's short term assets (NGN353.3M) exceed its long term liabilities (NGN18.1M).
Debt to Equity History and Analysis
Debt Level: PHARMDEKO's debt to equity ratio (1.4%) is considered satisfactory.
Reducing Debt: PHARMDEKO's debt to equity ratio has reduced from 5.5% to 1.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if PHARMDEKO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PHARMDEKO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Pharma Deko current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHARMDEKO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHARMDEKO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHARMDEKO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHARMDEKO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PHARMDEKO is not paying a notable dividend for the NG market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHARMDEKO's dividend in 3 years as they are not forecast to pay a notable one for the NG market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Isola Oluwole Olukayode serves as Managing Director at Pharma-Deko Plc and serves as Director since November 12, 2020 and served as Acting General Manager of Production Consumer/Contract and Acting Gen...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharma Deko Plc's employee growth, exchange listings and data sources
- Name: Pharma Deko Plc
- Ticker: PHARMDEKO
- Exchange: NGSE
- Founded: 1962
- Industry: Soft Drinks
- Sector: Food, Beverage & Tobacco
- Market Cap: ₦564.022m
- Shares outstanding: 216.93m
- Website: https://www.pharmadekoplc.com
Number of Employees
- Pharma Deko Plc
- Plot C1/1
- Agbara Industrial Estate
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 20:59|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.